MRSA

Protecting the host against bacterial virulence factors

Methicillin-resistant (i.e., multiresistant) Staphylococcus aureus (MRSA) is a frequent challenge to hospitalized patients, causing difficult-to-treat and often lethal infections of the lung, the heart, bones and the skin. MRSA releases toxins that damage or even kill host cells, including mediators of the immune response. Using nanobodies, we are targeting the toxins of MRSA, thereby counteracting pathogenic mechanisms and restoring the host defense.